Medical/Pharmaceuticals

"Gowajee" - a Thai Speech-Recognition AI from Chula

BANGKOK, Dec. 15, 2022 /PRNewswire/ -- Chula Engineering professors have designed "Gowajee", a Thai-language speech recognition AI with the accuracy of a native speaker that keeps users' data secure – now rolled out in call centers, and being used for depression patients screening.

2022-12-15 09:00 3340

Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease

ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other m...

2022-12-15 08:00 3986

Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund

SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- Alternative Bio Inc. ("ABio"), a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced today its $15 million Series Seed financing co-led by Eight Roads Ve...

2022-12-15 08:00 2959

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically validated mRNA platform is shown to generate differentiated products across a range of indications SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest M...

2022-12-15 08:00 6384

Novavax Announces Proposed $125 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its c...

2022-12-15 05:39 3790

Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ

Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock...

2022-12-14 23:47 2521

Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs)with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at...

2022-12-14 21:00 1789

BPK9 International Hospital Achieves GHA Accreditation for Medical Travel Services

PALM BEACH GARDENS, Fla., Dec. 14, 2022 /PRNewswire/ -- Global Healthcare Accreditation (GHA) is pleased to announce that BPK9 International Hospital in Bangkok, Thailand (https://www.bangpakokhospital.com/en/ ) is awarded with GHA Accreditation for Medical...

2022-12-14 19:00 2607

Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...

2022-12-14 15:17 4334

CGTN: 'New Approaches': Hospitals gear up to prioritize COVID-19 patients

BEIJING, Dec. 14, 2022 /PRNewswire/ -- To echo China's new guidelines for COVID-19 prevention and control, local governments and hospitals across the country have been optimizing medical services and the allocation of medical resources to face a likely surge in patients and take better care of th...

2022-12-14 12:36 2714

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

GERMANTOWN, Md. and HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...

2022-12-14 01:41 4079

Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor

NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers, today announced a presentation for the Company's CFI-400945 program, a first in class inhibitor of Polo-like Kinase ...

2022-12-13 22:30 4407

VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry

VeriSIM Life eliminates waste and inaccuracy, accelerates preclinical development, and lowers costs and risks when converting drug candidates to clinical trials, and brings life-saving drugs to market faster. SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the artif...

2022-12-13 21:00 1901

HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors

Financings Planned to Support Rapid Expansion of Histotripsy Platform as Company Welcomes Silk Road Medical CEO,Erica Rogers, to its Board of Directors MINNEAPOLIS, Dec. 13, 2022 /PRNewswire/ -- HistoSonics, Inc. ( www.histosonics.com ), the developer of a non-invasive...

2022-12-13 20:00 2196

CUVET Successfully Developed the First Stem Cell Transplantation Technology to Treat Pet Diabetes

BANGKOK, Dec. 13, 2022 /PRNewswire/ -- For the first time in Thailand, a research team from Chula's Faculty of Veterinary Science (CUVET), led by Assistant Professor Dr. Chenpop Sawangmek in collaboration with Bio ink Co., Ltd., a Chula spinoff company, has successfully developed a method to cultu...

2022-12-13 17:35 3087

RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced onDecember 7, 2022, that its latest antibody-drug conjugate (ADC), RC118 for injection, has been grante...

2022-12-13 12:30 2336

Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the "We Care About Mental Health" Initiative

* Luye Pharma has granted DCH Auriga Singapore exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in Singapore. * The two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative. SINGAPORE ...

2022-12-13 12:14 5080

Youth at Risk of Being Left Behind in Asia Pacific Tuberculosis Response, Regional Forum Spotlights

Johnson & Johnson, together with the Global Fund and Asian Venture Philanthropy Network, convene 2nd annual Asia Pacific Tuberculosis Forum to advance progress toward ending tuberculosis in the region Youth are at risk of being missed from diagnosis if not engaged and empowered in fight against ...

2022-12-13 10:07 2934

CSL Announces Next CEO & Managing Director

Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from6 March 2023 MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed DrPaul McKenzie as Chief Executive Officer (CEO)...

2022-12-13 07:23 3659

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Researchers from City of Hope find only 30% of people with neuroendocrine tumors consider living longer to be their single top priority; 70% said addressing and overcoming pain, fatigue, or lack-of-function was more important than just prolonging life. JNCCN announces five new Associate Editors ...

2022-12-13 06:19 1694
1 ... 150151152153154155156 ... 399